Detection and Diagnosis of Pancreatic Cancer

胰腺癌的检测和诊断

• 批准号: 6915870
• 负责人: DAVID V GOLD
• 金额: $ 26.62万
• 依托单位: CTR FOR MOLECULAR MEDICINE/IMMUNOLOGY
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-09-09 至 2009-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6915870
• 关键词: antigen antibody reaction; athymic mouse; biomarker; cell line; clinical research; diagnosis design /evaluation; early diagnosis; enzyme activity; glycosidases; glycosyltransferase; human tissue; immunocytochemistry; microarray technology; monoclonal antibody; mucins; neoplasm /cancer classification /staging; neoplasm /cancer immunodiagnosis; neoplasm /cancer immunology; oligosaccharides; pancreas neoplasms; posttranslational modifications; protein quantitation /detection; tumor antigens; xenotransplantation

DESCRIPTION (provided by applicant): Pancreatic cancer is one of the most insidious forms of cancer. Recent estimates of new cancer cases put pancreatic cancer at eighth and ninth among women and men, respectively. However, it is the fourth leading cause of all cancer deaths in both women and men, surpassed only by lung, colorectal, prostate, and breast cancers. Due largely to the location, and silent growth of the tumor, most patients present at a time when it is too late to undergo any realistic type of curative treatment. This has translated into a 5-year survival rate of less than 3%. In a recent report, "Pancreatic Cancer: An Agenda for Action", the NCI's Pancreatic cancer Progress Review Group drew specific attention to the urgent need for "better screening and diagnostic techniques" with a recommendation to "delineate and validate effective molecular biomarkers" for pancreatic cancer. With this in mind, we intend to develop and assess the utility of a PAM4, anti-MUC1 antibody-based immunoassay to detect, diagnose, and provide for the management of this disease. Although there have been several reports concerning anti-MUC1 MAbs reactive with several types of cancer, PAM4 appears to be unique, or nearly so, in terms of its specificity and the molecular characteristics of the epitope to which it is reactive. The long-term objective of this proposal is to identify specific biomarkers that can be combined with the PAM4 assay for enhanced diagnostic accuracy of pancreatic cancer. The specific aims of this proposal are Aim 1. To investigate the diagnostic accuracy of an immunoassay for the quantitation of PAM4-reactive MUC1 in biological fluids as a means for early detection and diagnosis of pancreatic cancer. Aim 2. To investigate the heterogeneity in expression of MUC1 epitope structures as a means to identify patterns that may be organ and/or tumor "specific/associated". Aim 3. To investigate whether inclusion of other mucin biomarkers can increase diagnostic accuracy through multivariate analyses.

描述（由申请人提供）：胰腺癌是最隐蔽的癌症形式之一。最近对新癌症病例的估计显示，胰腺癌在女性和男性中分别排名第八和第九。然而，它是女性和男性所有癌症死亡的第四大原因，仅次于肺癌、结直肠癌、前列腺癌和乳腺癌。主要由于肿瘤的位置和无声生长，大多数患者出现时已经太晚而无法接受任何实际类型的治疗。这意味着 5 年生存率低于 3%。在最近的一份报告《胰腺癌：行动议程》中，NCI 胰腺癌进展审查小组特别关注对“更好的筛查和诊断技术”的迫切需要，并建议“描述和验证有效的分子生物标志物”胰腺癌。考虑到这一点，我们打算开发和评估基于 PAM4（抗 MUC1 抗体）的免疫测定法的实用性，以检测、诊断和管理这种疾病。尽管已经有一些关于抗 MUC1 单克隆抗体与多种类型的癌症发生反应的报道，但 PAM4 就其特异性和与其反应的表位的分子特征而言似乎是独特的，或几乎是独特的。该提案的长期目标是确定可与 PAM4 检测相结合的特定生物标志物，以提高胰腺癌的诊断准确性。该提案的具体目标是目标 1：研究生物体液中 PAM4 反应性 MUC1 定量免疫测定的诊断准确性，作为早期检测和诊断胰腺癌的手段。 目标 2. 研究 MUC1 表位结构表达的异质性，作为识别可能是器官和/或肿瘤“特异性/相关”的模式的手段。目标 3. 通过多变量分析研究纳入其他粘蛋白生物标志物是否可以提高诊断准确性。